NCT02689219 2019-12-10Brentuximab Vedotin in Relapsed/Refractory Germ Cell TumorsIndiana UniversityPhase 2 Terminated18 enrolled 13 charts
NCT01851200 2018-02-07Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell TumorsFondazione MichelangeloPhase 2 Completed9 enrolled